Skip to main content
. 2017 Sep 7;21:234. doi: 10.1186/s13054-017-1823-x

Fig. 2.

Fig. 2

Change from baseline in plasma concentrations of angiotensin II (Ang II) (a), Ang 1–7 (b), and Ang 1–5 (c) following treatment with placebo or GSK2586881 (recombinant human angiotensin-converting enzyme 2 [rhACE2]). Data are expressed as adjusted median ± 95% credible interval (CrI). n* is number of subjects available for each measurement